Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: J Genet Couns. 2019 Sep 3;28(6):1107–1118. doi: 10.1002/jgc4.1161

Figure 2. Insurance coverage barriers to clinical WES.

Figure 2.

(a) Payer types for patients with insurance coverage barriers to WES. The majority had a public insurance policy (44/66, 67%). The remainder had a private insurance policy (17/66, 26%). The identity of the payer was unknown for a minority (5/66, 8%).

(b) Nature of insurance coverage barrier for patients without prior WES. The majority of patients (42/66, 64%) had documented denial of WES. The remainder either had an insurance type with a policy known not to cover WES (19/66, 29%) or had previous denial of a genetic test such as multi-gene panel (5/66, 8%).